Back to top
more

Shire plc (SHPG)

(Delayed Data from NSDQ)

$179.20 USD

179.20
NA

0.00 (0.00%)

Updated Jan 4, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall

by Zacks Equity Research

Allergan (AGN) lost a patent infringement lawsuit filed against companies trying to develop a generic version of its eye drug, Restasis, which is also its second bestselling drug.

    Shire's New Formulation of Oncaspar Gets CHMP Recommendation

    by Zacks Equity Research

    Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.

      Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat

      by Zacks Equity Research

      Keryx (KERX) is working on expanding its only marketed product, Auryxia's label.

        Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe

        by Zacks Equity Research

        Nektar (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.

          Is Shire plc (SHPG) a Suitable Value Stock?

          by Zacks Equity Research

          Shire is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

            Supernus Drops SPN-810's Lower Dose Test in Phase III Trials

            by Zacks Equity Research

            Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.

              Neos Therapeutics ADHD Drug Adzenys Receives Approval in US

              by Zacks Equity Research

              Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.

                Mark Vickery headshot

                Top Research Reports for Disney, Kraft Heinz & CVS Health

                by Mark Vickery

                Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Kraft Heinz (KHC) and CVS Health (CVS).

                  Alnylam Shares Plunge on Patient Death, Dosing Suspended

                  by Zacks Equity Research

                  Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.

                    Roche (RHHBY) Hemophilia A Drug Granted Priority Review

                    by Zacks Equity Research

                    Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.

                      Shire Files Marketing Application for Lifitegrast in Europe

                      by Zacks Equity Research

                      Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.

                        Will Nektar's (NKTR) Candidates Enhance Growth in 2017?

                        by Zacks Equity Research

                        Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.

                          Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls

                          by Zacks Equity Research

                          Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

                            Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

                            by Zacks Equity Research

                            Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.

                              Allergan (AGN) Q2 Earnings & Sales Top, Restasis Sales Down

                              by Zacks Equity Research

                              Allergan plc (AGN) beat estimates for both earnings and sales in Q2. The company raised its 2017 outlook. Shares were down slightly in pre-market trading.

                                New Strong Sell Stocks for July 20th

                                by Zacks Equity Research

                                Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                  Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

                                  by Zacks Equity Research

                                  Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

                                    Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data

                                    by Zacks Equity Research

                                    Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.

                                      Alnylam Commences Phase III Study for Hemophilia Candidate

                                      by Zacks Equity Research

                                      Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran.

                                        Shire Completes NDA Filing for Hemophilia Drug with FDA

                                        by Zacks Equity Research

                                        Shire plc (SHPG) recently announced that it has filed an investigational new drug (IND) application with the FDA, seeking approval for its recombinant factor VIII (FVIII) gene therapy candidate, SHP654, for the treatment of patients with Hemophilia A.

                                          KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline

                                          by Zacks Equity Research

                                          KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.

                                            Kamada Withdraws Inhaled AAT Marketing Application in EU

                                            by Zacks Equity Research

                                            Kamada Ltd.'s (KMDA) decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.

                                              Shire (SHPG) Receives MAA Validation for Veyvondi by EMA

                                              by Zacks Equity Research

                                              Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.

                                                Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US

                                                by Zacks Equity Research

                                                Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older

                                                  Could Shire PLC (SHPG) Be a Great Stock for Value Investors?

                                                  by Zacks Equity Research

                                                  Shire is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.